Neuromed's Extended Release Hydromorphone Gets Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Exalgo will be another test of FDA's willingness to approve opioids in the absence of a class-wide REMS.
You may also be interested in...
Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA
FDA signaled it is moving ahead with action on short-acting opioid products - and their Risk Evaluation and Mitigation Strategies - on a case-by-case basis with the approval of BioDelivery Sciences International's buccal fentanyl product Onsolis for cancer breakthrough pain
Deals Of The Week: J&J/TB Alliance, Watson/Arrow, GSK/Dr. Reddy's...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com/.
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins